AstraZeneca's camizestrant, an oral selective estrogen receptor degrader (SERD), is under FDA ODAC review on April 30, 2026, for HR-positive, HER2-negative advanced breast cancer with ESR1 mutations, in combination with CDK4/6 inhibitors.234
The SERENA-6 Phase III trial showed a 56% reduction in progression-free survival (PFS) risk with ctDNA-guided early switching, but FDA questions the novel design lacking comparison to treat-upon-radiographic-progression and notes immature overall survival (OS) data.247
FDA briefing documents highlight concerns over arrhythmia risks, no crossover in control arm, and whether early switching maximizes treatment benefits, with no prior approvals for ESR1-based switching before progression.24
Market consensus on Polymarket leans against FDA approval by May 14, 2026, due to regulatory skepticism on trial design and benefit-risk profile.3
ODAC meeting also reviews AstraZeneca's Truqap (capivasertib) for prostate cancer, but primary focus is camizestrant; no specific recent news on Newron, Gilead, or OSR in results.45
Sources:
2. https://oncodaily.com/oncolibrary/breast-oncology/camizestrant-fda
3. https://polymarket.com/event/fda-approves-astrazenecas-camizestrant
4. https://www.fiercebiotech.com/biotech/fda-flags-concerns-astrazeneca-camizestrant-truqap-ahead-advisory-committee-meeting
5. https://www.pharmanow.live/latest-news/odac-resumes-astrazeneca-camizestrant-nda-review-2026
7. https://insights.citeline.com/pink-sheet/product-reviews/us-advisory-committees/us-fdas-deep-skepticism-of-azs-novel-camizestrant-trial-design-signals-adcomm-trouble-CBIGSUS6YBC2NEVTJYZ6ZZ3RD4/